118 related articles for article (PubMed ID: 32763003)
21. Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non-Small Cell Lung Cancer.
Brooks GA; Austin AM; Uno H; Dragnev KH; Tosteson ANA; Schrag D
JAMA Netw Open; 2018 Oct; 1(6):e183023. PubMed ID: 30646220
[TBL] [Abstract][Full Text] [Related]
22. [Clinical efficacy of vitamin support in lung adenocarcinoma patients treated with pemetrexed second-line chemotherapy].
Zeng X; Zhou C; Ouyang M; Qin Y; Yang H; Peng Y; Liu S
Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):868-72. PubMed ID: 26887521
[TBL] [Abstract][Full Text] [Related]
23. Pemetrexed-induced severe rhabdomyolysis in lung cancer: A case report.
Sullivan K; Lee CS
J Oncol Pharm Pract; 2019 Dec; 25(8):2007-2009. PubMed ID: 30501380
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer.
Clarke SJ; Abratt R; Goedhals L; Boyer MJ; Millward MJ; Ackland SP
Ann Oncol; 2002 May; 13(5):737-41. PubMed ID: 12075742
[TBL] [Abstract][Full Text] [Related]
25. Inflamed Actinic Keratoses After Pemetrexed.
Cameron MC; Suárez AL; Kris MG; Myskowski PL
Skinmed; 2016; 14(6):473-474. PubMed ID: 28031141
[TBL] [Abstract][Full Text] [Related]
26. Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.
Shen L; Niu X; Jian H; Xu Y; Yu Y; Lu S
Lung Cancer; 2017 Sep; 111():43-50. PubMed ID: 28838396
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of Risk Factors for Side Effects and the Establishment of Supportive Therapy during Cancer Chemotherapy].
Sakurada T
Yakugaku Zasshi; 2018; 138(11):1363-1370. PubMed ID: 30381644
[TBL] [Abstract][Full Text] [Related]
28. Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Chen CY; Lin JW; Huang JW; Chen KY; Shih JY; Yu CJ; Yang PC
Clin Lung Cancer; 2015 Nov; 16(6):e131-40. PubMed ID: 25659505
[TBL] [Abstract][Full Text] [Related]
29. Epiphora following chemotherapy with pemetrexed in patients with advanced non-small cell lung cancer.
Jung YD; Lee SB; Jung YW; Song JS; Woo IS
Korean J Intern Med; 2017 Sep; 32(5):923-925. PubMed ID: 28298078
[No Abstract] [Full Text] [Related]
30. Pemetrexed-induced Interstitial Lung Disease Mimicking Hypersensitivity Pneumonia: A Pathologically Proven Case.
Otoshi R; Sekine A; Hagiwara E; Okudela K; Katano T; Aiko N; Matama G; Isomoto K; Ikeda S; Baba T; Komatsu S; Ogura T
Intern Med; 2019 Sep; 58(18):2679-2682. PubMed ID: 31178492
[TBL] [Abstract][Full Text] [Related]
31. Pemetrexed-Associated Eyelid Edema: Effective Treatment by Excision of Lymphedematous Eyelid Tissue.
Mangla N; Carlson A; Wakil A; Wu N; Wladis EJ
Ophthalmic Plast Reconstr Surg; 2015; 31(6):e155-7. PubMed ID: 24911536
[TBL] [Abstract][Full Text] [Related]
32. Toxic epidermal necrolysis after pemetrexed and cisplatin for non-small cell lung cancer in a patient with sharp syndrome.
Then C; von Einem JC; Müller D; Flaig MJ; Huber RM; Reincke M
Onkologie; 2012; 35(12):783-6. PubMed ID: 23207626
[TBL] [Abstract][Full Text] [Related]
33. Impact of pemetrexed chemotherapy on the gut microbiota and intestinal inflammation of patient-lung-derived tumor xenograft (PDX) mouse models.
Pensec C; Gillaizeau F; Guenot D; Bessard A; Carton T; Leuillet S; Campone M; Neunlist M; Blottière HM; Le Vacon F
Sci Rep; 2020 Jun; 10(1):9094. PubMed ID: 32499509
[TBL] [Abstract][Full Text] [Related]
34. Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma.
Huang XE; Tian GY; Cao J; Xu X; Lu YY; Wu XY; Liu J; Shi L; Xiang J
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6663-7. PubMed ID: 24377585
[TBL] [Abstract][Full Text] [Related]
35. Pneumatosis Intestinalis in Lung Cancer Induced Twice by Different Drugs: Bevacizumab and Pemetrexed.
Nunomiya K; Inoue S; Sato K; Igarashi A; Yamauchi K; Abe Y; Watanabe M
Intern Med; 2021 Jul; 60(13):2109-2113. PubMed ID: 33551401
[TBL] [Abstract][Full Text] [Related]
36. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
[TBL] [Abstract][Full Text] [Related]
37. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.
Ciuleanu T; Brodowicz T; Zielinski C; Kim JH; Krzakowski M; Laack E; Wu YL; Bover I; Begbie S; Tzekova V; Cucevic B; Pereira JR; Yang SH; Madhavan J; Sugarman KP; Peterson P; John WJ; Krejcy K; Belani CP
Lancet; 2009 Oct; 374(9699):1432-40. PubMed ID: 19767093
[TBL] [Abstract][Full Text] [Related]
38. A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed.
D'Angelo SP; Kris MG; Pietanza MC; Rizvi NA; Azzoli CG
J Thorac Oncol; 2011 Mar; 6(3):624-6. PubMed ID: 21317741
[TBL] [Abstract][Full Text] [Related]
39. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
[TBL] [Abstract][Full Text] [Related]
40. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.
Pujol JL; Paul S; Chouaki N; Peterson P; Moore P; Berry DA; Salzberg M
J Thorac Oncol; 2007 May; 2(5):397-401. PubMed ID: 17473654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
